The consumption of therapeutic products is meant for a particular objective. Along with their effectiveness in the treatment of a specific illness, they should be safe for intake. The aspect of safety is not only for the available medications in the market but also for the developing medications and the ones in different developmental stages.…

Systematic exploration of novel treatments, interventions, or medications in humans are a part of the clinical trials for determination of their efficacy, safety, and probable side effects. The populace of clinical trials is comprised of adults belonging to a healthy population and also participants with underlying diseases for evaluation of the efficacy and safety of…

Children constitute a special population in society and any experimentation in this population must be considered judiciously. In drug development participation of children is considered under exceptional conditions such as the potential drug is specifically developed for the pediatric population and the particular disease is most common in children. The pediatric research programs are governed…

In reaction to the shifts in the environment, the regulatory structure for medications is fast altering. The pharmaceutical industry is becoming increasingly globalized, there is an increase in digital technology and internet use, along with the changes in the lifestyle and habits of the patient populations bringing in remarkable shifts in the communities. The rapid…

Clinical trials are tedious, time-consuming and require robust mechanisms for ensuring patient retention in the study. For patients, frequent visits to the study site results in loss of time, effort as well as sometimes absenteeism at work. These are few of the reasons that patients drop-out from the study resulting in study data with lower…

After understanding the blog on the definition of (DCTs) decentralized clinical trials, the present blog depicts the utility of the (DCTs) decentralized clinical trials and their consolidated benefits. There are several compelling reasons that have made DCTs popular, and the clinical trial industry is striving to adopt this advancing technology. DCTs help enhance the efficiency…

Clinical trials are one of the most critical and difficult parts of the drug development process. The outcome from the clinical trial determines the next steps of development. Thus, credibility of the data is dependent on the quality of study conduct and the quality of data collected as part of the planned research programs. The…

A change has been noted over the past few years in the clinical trials ground, denoted by a generous alteration brought about by the rise of decentralized clinical trials (DCTs). These methodologies are inventive in nature and use technology and involve locally available healthcare providers to assist in clinical research by directly accessing patients and…

Drug registration in Brazil opens the opportunity to penetrate in the South American market. Brazil is one of the BRICs countries with the sixth-biggest population in the world and the largest economy.  Brazil has a population with a lot of unmet medical needs and requires access to novel medical therapies and treatment. Contrary to the…

The backbone of implementing Decentralized clinical trials (DCTs) is the efficiently running digital platform. DCT requires a customized DCT platform that has capability to receive and transmit the data accurately from various sources. Thus, DCT is an innovative shift in the traditional paradigm of clinical research, leveraging technology to facilitate remote participation and data collection.…